Unveiling the Potential Drug Target and Biomarker IGHV3-36: A Weakly Expressed Geneside in Humans

Target Name: IGHV3-36

NCBI ID: G28431

IGHV3-36

Other Name(s): Immunoglobulin heavy variable 3-36 (pseudogene) | immunoglobulin heavy variable 3-36 (pseudogene) | 3-36P | IGHV336

Unveiling the Potential Drug Target and Biomarker IGHV3-36: A Weakly Expressed Geneside in Humans

Immunoglobulin heavy variable 3-36 (IGHV3-36), also known as human acute myeloid leukemia (AML) gene 13, is a highly conserved non-coding RNA molecule that plays a crucial role in the development and progression of various hematological malignancies, including AML. IGHV3-36 is a unique pseudogene, which means it is a non-coding RNA molecule that has a protein coding gene (IGHV3-36 gene) upstream. Despite its prominent involvement in hematological diseases, IGHV3-36 has not yet been assigned a specific function or mechanism of action, and its potential as a drug target or biomarker remains unexplored.

Expression and Localization of IGHV3-36

IGHV3-36 is a highly expressed gene in human tissues, including blood cells, tissue cells, and various organs. It is expressed at levels ranging from a few hundred to several thousand copies per million, depending on the specific cell type and developmental stage. IGHV3-36 is primarily expressed in the nucleus and is also found in the cytoplasm of these cells. Its expression pattern is highly conserved across various human tissues and is consistent with its role in hematological development and progression.

Despite its widespread expression, IGHV3-36 is well-localized to specific cell types and cellular processes. IGHV3-36 is primarily expressed in hematopoietic stem cells (HSCs), which are responsible for the production of all blood cells. It is also expressed in normal peripheral blood cells and in various tissues that support the immune system, such as the spleen, lymph nodes, and bone marrow. These localizations suggest that IGHV3-36 may be involved in the regulation of hematopoietic stem cell (HSC) proliferation and differentiation, as well as immune cell function.

Function and Potential Therapeutic Applications

The potential therapeutic applications of IGHV3-36 are vast, as it is involved in several critical cellular processes that are crucial for human health and disease. IGHV3-36 is a key regulator of the cell cycle, and its expression is highly correlated with the length of the cell cycle. It is involved in the regulation of DNA replication, cell division, and apoptosis, which are all critical for the development and maintenance of tissues and organs.

IGHV3-36 has also been shown to play a crucial role in the regulation of immune cell function. It is a key regulator of B cell development and activation. IGHV3-36 is expressed in a variety of immune cells, including lymphocytes, macrophages, and dendritic cells, and its expression is closely correlated with the production of antibodies and the activation of these cells.

In addition to its role in immune cell function, IGHV3-36 has also been shown to play a critical role in the regulation of inflammation and immune tolerance. It is involved in the regulation of pro-inflammatory and anti-inflammatory responses, as well as the regulation of immune tolerance.

Molecular Mechanisms

The molecular mechanisms underlying the regulation of IGHV3-36 are not well understood, and further research is needed to determine the precise role of this gene in human health and disease. One potential mechanism by which IGHV3-36 may be involved in its regulation is through the regulation of DNA replication. IGHV3-36 has been shown to play a crucial role in the regulation of DNA replication in various cell types, including HSCs.

Another potential mechanism by which IGHV3-36 may be involved in its regulation is through

Protein Name: Immunoglobulin Heavy Variable 3-36 (pseudogene)

The "IGHV3-36 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV3-36 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets